Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector  by Wollmann, Guido et al.
Attenuation of vesicular stomatitis virus infection of brain using
antiviral drugs and an adeno-associated virus-interferon vector
Guido Wollmann, Justin C. Paglino, Patrick R. Maloney, Sebastian A. Ahmadi,
Anthony N. van den Pol n
Department of Neurosurgery, Yale University School of Medicine, New Haven, CT 06520, United States
a r t i c l e i n f o
Article history:
Received 9 September 2014
Returned to author for revisions
4 October 2014
Accepted 20 October 2014
Available online 21 November 2014
Keywords:
Oncolytic virus
VSV
Antiviral
Brain
Interferon
Ribavirin
AAV
a b s t r a c t
Vesicular stomatitis virus (VSV) shows promise as a vaccine-vector and oncolytic virus. However, reports
of neurotoxicity of VSV remain a concern. We compared 12 antiviral compounds to control infection of
VSV-CT9-M51 and VSV-rp30 using murine and human brain cultures, and in vivo mouse models.
Inhibition of replication, cytotoxicity and infectivity was strongest with ribavirin and IFN-α and to some
extent with mycophenolic acid, chloroquine, and adenine 9-β-D-arabinofuranoside. To generate con-
tinuous IFN exposure, we made an adeno-associated virus vector expressing murine IFN; AAV-mIFN-β
protected mouse brain cells from VSV, as did a combination of IFN, ribavirin and chloroquine.
Intracranial AAV-mIFN-β protected the brain against VSV-CT9-M51. In SCID mice bearing human
glioblastoma, AAV-mIFN-β moderately enhanced survival. VSV-CT9-M51 doubled median survival when
administered after AAV-mIFN-β; some surviving mice showed complete tumor destruction. Together,
these data suggest that AAV-IFN or IFN with ribavirin and chloroquine provide an optimal anti-virus
combination against VSV in the brain.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The brain is a unique organ with respect to virus infection. The
blood–brain barrier restricts entry of many viruses; on the other
hand, CNS neurons do not replicate, may not express MHC proteins,
and antibodies and cells of the immune system may operate in
restricted manners within the brain (Paul et al., 2007). The brain
can show enhanced sensitivity to both viruses and antiviral drugs.
Virus or drug-induced apoptosis may be much more detrimental in
the brain than in other organs due to the general lack of neuron
replenishment in most regions of the adult brain (Bechmann, 2005).
Vesicular stomatitis virus (VSV) has emerged as a promising
candidate in two ﬁelds, as a broad-spectrum oncolytic virus and as
a potent vaccine vector (Barber, 2004; Geisbert and Feldmann, 2011;
Lichty et al., 2004; McKenna et al., 2003; Roberts et al., 1999; Rose
et al., 2001). VSV combines a number of favorable characteristics for
future potential therapeutic application, including broad cell and
tissue tropism, the absence of nuclear integration with risk of cell
transformation, a small and well-studied genome accessible for
genetic engineering, a largely non-pathogenic nature in humans,
optional rapid or inactive replication cycle, and low pre-existing
immunity in most of the population (Hastie and Grdzelishvili, 2012).
VSV has shown efﬁcacy in animal models of glioblastoma, with an
ability to achieve selective infection within a brain tumor even after
intravenous inoculation (Ozduman et al., 2008). However, potential
neurotoxicity, particularly after intranasal or intracranial application
(Johnson et al., 2007; van den Pol et al., 2002), remains a potential
complication. Application of VSV as an oncolytic agent outside the
brain is currently being tested in a clinical trial (NCT 01628640) for
liver cancer using an attenuated recombinant VSV-IFN-β designed to
express interferon to boost an antiviral defense in normal cells.
VSV is a negative-strand RNA virus of the Rhabdovirus family
primarily infecting cattle, horses, and other livestock and their
corresponding insect vectors. It causes mostly mild disease with
ﬂu-like symptoms and blistering stomatitis. The viral 11 kb genome
contains 5 genes, which encode 5 viral proteins: N, P, M, G, and L
(Lyles and Rupprecht, 2007). Several attenuation strategies have been
pursued in recent years resulting in a number of VSV variants with
decreased neurotoxicity. For instance, VSV-M51 mutants reduce the
virus' ability to counter cellular antiviral responses (Stojdl et al.,
2003); truncated G protein variants such as VSV-CT9 (Publicover
et al., 2004) result in slower replication cycles as do genome shifting
variants VSV-10GFP or VSV-120GFP (van den Pol and Davis, 2013;
Wollmann et al., 2010) and genome shufﬂed variants (Clarke et al.,
2007; Flanagan et al., 2001); variants pseudotyped with LCMV G
protein in place of VSV G protein show reduced tropism to neurons
(Muik et al., 2011), and G-protein deleted variants show effectiveness
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as a single round agent without consecutive spread (Publicover et al.,
2005; van den Pol et al., 2009). The combination of two replication-
restricted gene-deleted VSVs to a semi-replication competent system
reduced neurotoxicity (Muik et al., 2012). Additionally, a VSV
engineered to express interferon, VSV-IFN, showed increased safety
in preclinical models after peripheral application, although neuro-
toxicity was still possible when the virus gained access to the CNS
(Yarde et al., 2013).
The generation and use of some attenuated VSV variants is based
on the view that VSV infection can be attenuated by an innate
immune response before the systemic immune response, generally
in the form of neutralizing antibodies, clears the virus infection. A
central mediator of the initial antiviral response to VSV is interferon
(IFN) (Detje et al., 2009). The ability of brain cells to mount an IFN
response differs in some aspects from cells outside the brain. For
instance, neurons are responsive to IFN signaling (Wang and
Campbell, 2005) but their contribution to local IFN production
varies with several factors (Delhaye et al., 2006; Kallfass et al., 2012;
Yin et al., 2009). Adaptive immunity can operate within the brain as
well: we have shown that peripheral immunization effectively
protects from VSV neurotoxicity after intracranial inoculation
(Ozduman et al., 2009). This pre-treatment immunization strategy,
however, may limit the efﬁcacy of some therapeutic VSV applica-
tions, thus there is a continued interest in how VSV neurotoxicity
could be abrogated in unvaccinated/VSV-naïve hosts. Therefore, we
addressed whether antiviral compounds could play a role in aiding
existing viral attenuation strategies to prevent or limit the extent of
VSV neurotoxicity.
We assessed the use of antiviral drugs both in vitro and in vivo
regarding their potential to inhibit VSV infection and replication
and VSV-associated morbidity. The 12 compounds tested were
chosen based on their previously reported antiviral effects on
peripheral or CNS infection of VSV or related viruses: IFN (Detje
et al., 2009; Wollmann et al., 2007), ribavirin (Toltzis and Huang,
1986; Willoughby Jr. et al., 2005), octyl gallate (Yamasaki et al.,
2007), mycophenolic acid (MPA) (Ye et al., 2012), dansylcadaverine
(Schlegel et al., 1982), rimantadine (Kolocouris et al., 1996), aman-
tadine (Schlegel et al., 1982; Superti et al., 1985; Willoughby Jr. et al.,
2005), adenine 9-β-D-arabinofuranoside (Ara-a) (Grant and Sabina,
1972), chloroquine (Dille and Johnson, 1982), acetylsalicylic acid
(aspirin) (Chen et al., 2000), adenosine (Schnitzlein and Reichmann,
1980), and S-nitroso-N-acetylpenicillamine (SNAP) (Bi and Reiss,
1995). These drugs act by a variety of mechanisms including
interfering with RNA metabolism and replication via nucleoside
analogs (ribavirin, Ara-A) or non-nucleoside inhibitors (mycophe-
nolic acid), delaying of viral replication (octyl gallate), inhibition of
virus internalization and uncoating (dansylcadaverine, amantadine,
rimantadine), G-protein processing (chloroquine), and nitric oxide
supply (SNAP). We tested these compounds for their in vitro
protection of human and mouse brain cell cultures against three
recombinant VSVs, the attenuated VSV-CT9-M51 (Wollmann et al.,
2010) and the tumor-adapted variant VSV-rp30 (Wollmann et al.,
2013) as well as its parent strain, VSV-G/GFP. In addition, the in vivo
efﬁcacy in protecting mouse brain from viral neurotoxicity was
examined. Finally, we generated an IFN-expressing AAV vector for
enhanced mouse IFN gene expression in mouse brain cells that gave
effective protection from neurotoxicity of intracranial injections of
VSV and also extended survival in VSV-CT9-M51-treated brain
tumor mouse models.
Results
Here we compare 12 drugs and compounds for their potential to
control the infection of VSV in human brain cultures and in mouse
brain. The 12 compounds were selected based on previously reported
antiviral properties against VSV, against related mononegaviridae
members, or against other RNA viruses. 11 compounds were selected
for comparison with interferon IFN-αA/D, a common agent used to
control VSV infection: ribavirin, octyl gallate (OG), mycophenolic acid
(MPA), dansylcadaverine (DC), rimantadine hydrochloride, amanta-
dine hydrochloride, adenine 9-β-D-arabinofuranoside (Ara-A), chlor-
oquine diphosphate, acetylsalicylic acid (ASA), adenosine, and
S-nitroso-N-acetylpenicillamine (SNAP). Later, we also tested a viral
vector that expresses interferon. Both mouse and human brain cells
were used in conjunction with recombinant VSVs.
Antiviral compound toxicity and dose response
To establish dose limits and adverse drug effects on human
brain cultures, we tested each drug at 5 concentrations in half log
dilution steps. Concentration ranges were set based on factors
including maximum solubility, maximum acceptable solvent con-
centration, and previously reported doses. Brain cultures consisted
of a number of cell types, with astrocytes being the most common.
Using the MTT assay, we identiﬁed the thresholds of toxicity in
these cultures after 48 h of incubation (Fig. 1). Of the 11 drugs
tested, MPA, ribavirin, Ara-A, adenosine, and SNAP did not gen-
erate cellular toxicity throughout the concentration range tested.
ASA showed a small decrease in viability at the highest concentra-
tion tested (10 mM). Amantadine, DC, rimantadine, chloroquine,
and OG were toxic to the cells in the highest one or two
concentrations. From these results, compound concentrations
were selected to combine with viral inoculation. ‘High’ drug
concentration was deﬁned as the highest non-toxic dose; ‘low’
drug concentration was 1 log lower (equivalent to 2 steps down
the tested concentration curve). In addition, IFN has been used in
our lab in concentrations well above 1000 IU per ml without
adverse effect in vitro. Here, we chose 100 IU per ml as a high dose
and 10 IU per ml as a low drug concentration. We also tested IFN
concentrations of 1 IU per ml independently to assess its potency
on human glia at a concentration that is deﬁned to reduce
infection of VSV-permissive cells by 50% (Pestka, 1986). Table 1
shows each drug with its corresponding high and low dose.
Antiviral effects of drug preincubation on human brain cultures
Normal human adult brain cultures at 80% conﬂuency were
treated with antiviral drug compounds 6 h prior to addition of
VSV-rp30 at an MOI of 1 pfu/cell. 48 h post infection cultures were
analyzed for viral infection and cytopathic effects using phase
contrast and ﬂuorescent microscope imaging. Fig. 2A shows VSV-
rp30 infection rates and infection induced cell toxicity in the
presence of high drug concentration, Fig. 2B shows results for low
drug concentration. In high drug conditions, Ara-A, chloroquine, and
ribavirin provided protection from infection and cell death compar-
able to 100 IU of IFN-α. High concentrations of MPA provided
signiﬁcant but incomplete protection from VSV infection (~35%
infected). With low drug concentrations, ribavirin and IFN showed
protection comparable to that seen in high drug conditions, whereas
MPA showed less but still signiﬁcant protection when compared to
high drug concentration. When we tested pre-incubation with as
little as 1 IU of IFN, we still found about a 50% protection from
infection (5679.6% GFP positive cells). Chloroquine and Ara-A had
little protective effect in low drug conditions. Adenosine, amantidine,
ASA, DC, OG, rimantadine, and SNAP showed little or no protection
from VSV-rp30 infection at high or low doses.
Representative micrographs of human brain cultures treated
6 h in advance with the respective high concentrations of highly
protective drug (ribavirin), a moderately effective drug (MPA) and
a non-effective drug (rimantadine) and infected with VSV-rp30 for
48 h are displayed in Fig. 3A. In addition to VSV-rp30, we also
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tested a double attenuated viral mutant VSV-CT9-M51 for GFP-
reported infectivity rates and virus induced cytopathic effects
(representative ﬁgures shown in Fig. 3A, left panels). Infectivity
rates were generally lower with VSV-CT9-M51 than for tumor-
adapted VSV-rp30. As with VSV-rp30, ribavirin and IFN provided
complete protection at both low and high drug concentration for
VSVCT9-M51.
Embryonic astrocytes may be more susceptible to viral infec-
tion compared to adult astrocytes in part because the IFN system
appears to mature with cell differentiation (Harada et al., 1990). In
parallel experiments we tested a selection of antiviral drugs for
their inhibitory effects on infection of normal human embryonic
astrocytes by VSV-CT9-M51 and VSV-rp30. We used an MTT assay
to assess viability of conﬂuent astrocyte cultures infected at an
MOI of 0.1 after 48 hpi. Fig. 3B summarizes triplicate tests run with
8 drugs at both high and low concentration. Similar to primary
cultures from adult human glia shown above, ribavirin again
provided signiﬁcant protection even at a low dose, and chloro-
quine was again protective only at a high dose. Dansylcadaverine
(DC) was protective (at a high dose). Ara-A and amantadine were
ineffective (even at a high dose). Similar ﬁndings were observed
for both VSV-rp30 and VSV-CT9-M51.
Antiviral drug effects on human glia cultures post viral inoculation
The set of experiments above focused on the screening of 12
agents for antiviral effects to protect human brain cells against
infection with VSV-CT9-M51 and VSV-rp30. In those experiments
Fig. 1. Dose range and toxicity studies. Eleven compounds were tested for in vitro toxicity on human astrocyte monolayers using MTT viability assay. Dose ranges consisted of
5 dosage steps diluted in half-log increments, starting from either maximum solubility concentration or previously reported toxic values. For subsequent experiments, high
drug concentration is deﬁned as the highest non-toxic concentration, low drug concentration as a 10-fold dilution of the respective high concentration (equivalent to
2 dilution steps from dose range curves shown here).
Table 1
List of antiviral compounds and concentrations used. High concentration was deﬁned as the highest non-toxic dose tested based on dose/viability studies in Fig. 1. Low
concentration represents the value of two dilution steps below respective high concentration. A possible mechanism of action for each compound is included; additional
mechanisms may also exist.
Compound Concentrations Mechanism
Adenosine 1 mM and 100 mM Inhibition of pyrimidine synthesis (Schnitzlein and Reichmann, 1980; Stollar and Malinoski, 1981)
Amantadine 1 mM and 100 mM Inhibition of endocytosis (Schlegel et al., 1982; Superti et al., 1985)
Ara-A 1 mM and 100 mM Inhibition of RNA synthesis (Grant and Sabina, 1972)
Aspirin 3 mM and 300 mM Promotion of NO synthesis (Chen et al., 2000)
Chloroquine 30 mM and 3 mM Inhibition of endosomal escape (Coombs et al., 1981; Dille and Johnson, 1982; Pérez and Carrasco, 1994)
Dansylcadaverine 100 mM and 10 mM Inhibition of endocytosis (Schlegel et al., 1982)
Interferon 100 U/ml and 10 U/ml Induction of antiviral genes (Detje et al., 2009; Wollmann et al., 2007)
Mycophenolic acid 300 mM and 30 mM Depletion of GTP (Ye et al., 2012)
Octyl-gallate 100 mM and 10 mM Unknown. Inhibits viral replication (Uozaki et al., 2007; Yamasaki et al., 2007)
Ribavirin 3 mM and 300 mM Pleiotropic effects. Guanosine analog (Toltzis and Huang, 1986; Hong and Cameron, 2002; Shah et al., 2010)
Rimantadine 300 mM and 30 mM Inhibition of endocytosis (Kolocouris et al., 1996; Mato et al., 1983; Schlegel et al., 1982)
SNAP 1 mM and 100 mM Organic NO donor (Bi and Reiss, 1995)
Abbreviations: Ara-A – adenine 9-β-D-arabinofuranoside; SNAP – S-nitroso-N-acetylpenicillamine; NO – nitric oxide.
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drugs were applied 6 h before virus was added. To test the ability of
the three most effective drugs, IFN, ribavirin, and MPA, to interfere
with an ongoing infection, we infected normal adult human glial cells
with VSV-rp30 at an MOI of 0.1 and added drugs in their respective
high concentrations at 0, 2, 4, and 6 h post virus inoculation (Fig. 4).
Cell viability was assessed using the MTT assay at 48 hpi. IFN was
effective in completely protecting viability of the cultures when
added up to 4 h post virus inoculation, with signiﬁcant protection
from VSV even after adding at 6 hpi. Though not complete, ribavirin
also provided signiﬁcant protection with over 80% viability when
added up to 6 h after virus application. In contrast, MPA showed a
protective effect (450% viability) when co-administered with the
virus, but its efﬁcacy decreased substantially when added 2 hpi, and
had almost no effect at later time points.
Antiviral drug effects on virus replication
In addition to infection rates and viability, we tested the effect
of 5 antiviral drugs on viral replication rates using a standard
plaque assay. Human astrocyte cultures were treated with respec-
tive high and low drug concentrations 6 h before addition of
VSV-rp30 at an MOI of 0.1. Supernatants were collected at 24
and 48 hpi, respectively, serially diluted, and plated onto a BHK
cell monolayer. Untreated, viral replication reached 3.65106 and
4.0106 PFU/ml for 24 hpi and 48 hpi, respectively (Fig. 5). Dan-
sylcadaverine had little effect on viral replication in both its low
and high concentration and at both time points. Adenosine was
minimally effective at low concentrations but showed a mildly
attenuating effect on viral replication at high concentration by
reducing the titer 4-fold at 24 hpi and 10-fold at 48 hpi. MPA
showed a strong reduction of viral titer by nearly three orders of
magnitude in both concentrations at 24 hpi. Interestingly, MPA
had a far more modest effect on viral titers at 48 h, with titers
reaching 5–10105 PFU/ml, suggesting an effect that is transient
and overcome by the virus after two days. Both IFN (not shown)
and ribavirin showed strong and lasting suppression of VSV
replication in both conditions with viral titers in the range of
1–8103 PFU/ml, similar to the range of initially applied VSV.
AAV-IFN vector protects mouse glia and neurons from VSV
Given the efﬁcacy of IFN at protecting human glia and neurons
from VSV, and the potential utility of AAV as an ongoing IFN delivery
vector, we asked whether a viral vector that expressed IFN could
protect mouse glia and neurons from VSV infection. We generated
AAV-mIFN-β, an AAV2-based self-complementary vector in which
murine IFN-β expression is driven by a CMV ie1 promoter. To serve as
a control for any effects of AAV-vector infection on subsequent VSV
Fig. 2. Effect of antiviral compounds on VSV infectivity and cytotoxicity on normal human glia cultures. Primary cultures of normal adult human brain tissue were infected
with VSV-rp30 at an MOI of 1 after 6 h preincubation with 12 antiviral compounds at high (A) or low (B) concentration. Infectivity was assessed through virus-mediated GFP
expression (left graphs), cytotoxicity through cellular cytopathic effects (rounding, blebbing) (right graphs). nnn indicates po0.001, ** indicates po0.01 signiﬁcance (n¼10;
ANOVA with Bonferroni post-hoc analysis).
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infection, we also constructed self-complementary AAV-tdTomato
in which the same promoter drives expression of the red ﬂuorescent
reporter tdTomato.
First, murine glial cultures were treated with AAV and incu-
bated for 10 days to allow transgene expression. By 3 days post-
inoculation with VSV-G/GFP, virus had infected and killed most
control glial brain cells (Fig. 6A–C, No Pretreatment). Control cells
not infected by VSV-G/GFP grew and replicated normally, as seen
in Fig. 6B and in the top panel of Fig. 6C. Cells pretreated with high
MOI AAV-mIFN-β (5,000 genomes/cell) were only very minimally
affected by VSV-infection; cell density 3 dpi did not differ from
that of uninfected control cells (Fig. 6B), and the percentage of
cells infected never exceeded 4%, and was less than 1% at 3 dpi
(Fig. 6A). Low MOI AAV-mIFN-β (500 genomes/cell) had a weaker
but still highly protective effect: cell density 3 dpi was 80% of that
of uninfected cells, and the percentage of cells infected was 3.1%.
Under phase contrast, AAV-mIFN-β-protected cell monolayers
appeared healthy and indistinguishable from untreated mono-
layers (Fig. 6C).
The control AAV vector not expressing IFN, AAV-tdTomato,
showed no efﬁcacy in protection from VSV; by 3 dpi after VSV
inoculation, the majority of cells (490%) were detached or
showed signiﬁcant cytopathic effects (CPE) (Fig. 6B), and most of
the cells were GFP-positive corroborating viral infection (Fig. 6A).
IFN-βA/D was effective at protecting glia when added 1 day before
VSV-infection, showing a degree of protection similar to AAV-
mIFN, however when added 10 days before VSV infection, the
same concentration of IFN only moderately protected cells, which
Fig. 3. Antiviral effects of compounds on attenuated VSV-CT9-M51 and tumor-adapted VSV-rp30. (A) Representative ﬂuorescence and phase contrast photomicrographs of
primary adult human glia cultures infected with VSV-CT9-M51 (left panel) or VSV-rp30 (right panel). Ribavirin preincubation completely protected the cultures from viral
infection. MPA protected from VSV-CT9-M51 infection with little effect on VSV-rp30 infection. Rimantadine had no protective effect. Scale bar 100 μm. (B) Graphs displaying
viability rates of normal embryonic human astrocytes infected with VSV-CT9-M51 (left) or VSV-rp30 (right) at MOI 0.1 using MTT viability after incubation with compounds
at low or high drug concentration respectively.
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decreased to less than 30% of their original density 3dpi, showed
marked cytopathic effects, and were 20% infected by VSV-G/GFP.
Together, these ﬁndings support the view that a single application
of AAV-mIFN-β protected brain cells from VSV-G/GFP, and that this
protection was substantially more effective and longer lasting than
a single application of exogenous IFN.
Mouse neuron cultures grown in Neurobasal medium that
favors neuronal survival over glia were pretreated with selected
antiviral compounds for 6 h; cultures treated with AAV-mIFN-β
were incubated for 10 days with the vector to allow sufﬁcient time
for gene expression. Treatment with chloroquine (CLQ; 30μM),
ribavirin (Rib; 300 μM), and IFN-αA/D (100 IU/ml) increased resis-
tance of neuronal cultures to infection of VSV-rp30 and VSV-CT9-
M51, respectively, at an MOI of 1 (Fig. 7A). In contrast, pretreat-
ment with MPA (300 μM) showed little effect on VSV infection. A
triple drug combination (CLQ-MPA-Rib) was comparable to riba-
virin alone. Cultures pretreated with AAV-IFN-β (5000 genomes
per cell) for 10 days showed robust resistance to VSV infection,
which could be enhanced to near full protection with consecutive
6 h pretreatment with ribavirin (300 μM). Thus a combination of
IFN, particularly based on AAV-IFN, together with ribavirin
appeared to be the most effective combination in blocking VSV
infection of neurons.
In order to assess the effect of antiviral drugs speciﬁcally on
identiﬁed neurons we used immunostaining for the selective
neuronal marker NeuN which is expressed only by neurons.
Mouse brain cultures enriched with neurons were infected with
VSV at an MOI 1 either in untreated control conditions or after
pretreatment with AAV-mIFN-β (5000 genomes/cell for 10 days),
ribavirin (300 μM for 6 h), universal IFN-αA/D (100 IU/ml for 6 h),
or AAV-mIFN-β combined with ribavirin. 20 h post-infection with
VSV-G/GFP, cells were ﬁxed and immunostained for NeuN
(Fig. 7C). Only NeuN-positive cells (neurons) were scored for GFP
positivity, indicating VSV-infection. Results are shown in Fig. 7B.
80% of untreated control neurons were infected with VSV under
these conditions; in contrast, only 3.6% of ribavirin protected cells
were infected. Similarly, VSV infected only 2.5% of neurons
protected by AAVmIFN-β, and only 1.8% of neurons protected by
a combination of AAVmIFN-β and ribavirin. Short-term IFN-
exposed neurons were partially protected with 33% showing
infection.
Antiviral compounds and AAV-mIFN-β protect brain from intracranial
VSV-CT9-M51 infection
We next tested the efﬁcacy of VSV-protective compounds and
AAV-mIFN-β in vivo, speciﬁcally their ability to protect animals from
the neurotoxicity of intracranial VSV-CT9-M51. In 10 adult mice, a
mixture of three of the most effective anti-VSV compounds was
injected into the striatum followed 15min later by intracranial VSV-
CT9-M51 challenge (1.5104 pfu in 250 nl). The antiviral drug cocktail
applied directly into the mouse brain was well tolerated in control
experiments and evoked no adverse effects (n¼5, Fig. 8A). 2.5 μl of
drug solutionwas injected containing IFN-αA/D (1000 IU)þribavirin
Fig. 4. Time course of antiviral effects of compounds added after virus inoculation of normal human glia cultures. To test the potential of antiviral compounds to attenuate an
ongoing infection of normal adult human glia cultures with VSV-rp30, drugs were applied at indicated time points after viral inoculation (MOI 0.1). Results are shown as
viability rates compared to non-infected control using MTT assay. Both interferon (IFN) and ribavirin (Rib) strongly attenuate VSV infection when added up to 6 hpi. MPA
shows some protection only if given at the same time or shortly after VSV-rp30 application. nnn indicates po0.001signiﬁcance; n.s.¼not signiﬁcant (n¼4; ANOVA with
Bonferroni post-hoc analysis).
Fig. 5. Suppression of VSV-rp30 replication in normal embryonic human astrocytes by selected antiviral compounds. The effect of selected antiviral compounds on VSV-rp30
replication rates on normal embryonic human astrocytes was tested using standard plaque assay. Ribavirin incubation strongly inhibited viral replication. MPA effectively
halted viral replication during the ﬁrst 24 h, but had less impact on replication after 48 h. Adenosine mildly attenuated viral replication at high concentration only.
nnn indicates po0.001signiﬁcance; *po0.05; n.s.¼not signiﬁcant (n¼4; ANOVA with Bonferroni post-hoc analysis).
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(7 mg/kg body weight)þchloroquine (30 mM); 10 control mice
received PBS injection before being injected with VSV-CT9-M51;
survival results are shown in Fig. 8B. The antiviral drug adminis-
tration signiﬁcantly extended survival of mice challenged with
intracranial VSV from a median of 6 days in controls to 13 days in
drug treated mice (p¼0.032; Log-rank test). In controls, VSV was
100% lethal by 8 dpi; 3 of 10 treated mice (30%) survived long-term
until the experiment was ended 55 dpi. Given the relative ease of
systemic administration clinically, we next tested if repeated
intraperitoneal (i.p.) drug administration could achieve a degree
of protection comparable to that conferred by intracranial admin-
istration. 5 mice challenged i.c. with VSV-CT9-M51 (1.5104 pfu in
250 nl) were treated i.p. with 500 μl of the drug mixture containing
IFN-αA/D (2500 IU)þribavirin (40 mg/kg)þchloroquine (50 mg/kg)
on days 0, 2, 4, and 6 post infection; survival results are shown in
Fig. 8C. 1 of 5 treated mice (20%) survived long term, not statistically
different from the 30% long-term survival seen after intracranial
drug administration (p¼0.9; Log-rank test). 1 of 10 control mice
(10%) survived long term in this experiment. Although the rate of
long-term survival was greater in drug-treated mice, this was not
statistically signiﬁcant in this experiment (p40.05; Log-rank test);
however, the median survival was noticeably extended in drug-
treated mice to 15 days compared to 6 days in non-treated mice.
In this same experiment, we also tested the ability of intracranial
AAV-mIFN-β to protect mice from i.c. VSV-CT9-M51 when AAV is
administered 14 days prior to VSV challenge, giving transduced cells
time to express the mIFN-β transgene. 2 μl (containing 21010
genomes) of AAV-mIFN-β were injected into the striatum of 10 adult
mice. 14 days later, these mice were given the same intracranial VSV-
CT9-M51 challenge as the other groups; survival data in Fig. 8C show
that all ten of the AAV-treated mice survived long-term until the
experiment was concluded 40 days after VSV inoculation. This
complete protection stood in clear contrast to the near 100% lethality
of VSV in unprotected animals (po0.0001). No neurological symp-
toms or obvious signs of distress were noted in mice having received
AAV-mIFN-β. In addition, as shown in Fig. 8D, AAV-protected mice
had no weight loss following VSV challenge, another indication of
VSV neurotoxicity being greatly diminished; both i.p. drug-treated
animals and control animals demonstrated signiﬁcant weight loss
immediately after VSV injection.
Fig. 6. AAV-mIFN-β protects mouse glia from VSV infection. After each pretreatment, as described in the text, mouse glia cultures were infected with VSV-G/GFP and
assessed daily for density of living cells (B) and percentage of cells infected (GFPþ) (A). Micrographs taken 3 dpi are shown in C. Error bars, SEM.
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Survival of glioma-bearing mice treated with systemic VSV-CT9-M51
is enhanced by intracranial AAV-mIFN-β
Orthotopic human gliomas in SCID mice are infected selectively
after systemic application of VSV (Ozduman et al., 2008). Although in
short term experiments lasting a few days, VSV initially infects only
the tumor and spreads selectively throughout the tumor, the concern
remains that over a longer period virus may spread into normal
tissue. Here we sought to mitigate this spread by pre-application of
AAV-mIFN-β, creating a zone of VSV-resistance in the vicinity of the
tumor. 15 mice received intracranial human glioblastoma rU87
expressing red ﬂuorescent protein as a reporter molecule; eight
were given 2 μl containing 21010 drp of AAV-mIFN-β 15 min before
tumor grafting at the same injection site; the remaining seven
control mice received PBS only. 14 days later, two AAV-treated mice
were euthanized with anesthetic overdose to corroborate successful
tumor grafts (Fig. 9C) and 13 mice were administered 3107 pfu of
VSV-CT9-M51 via tail vein injection; survival results are shown in
Fig. 9A. Mice showing substantial weight loss (425% body weight
reduction), or any neurological symptom including limb paralysis
were euthanized, and for the sake of this analysis, were included in
the adverse lethal response group.
Whereas mice not protected by AAV-mIFN-β began to die
within 8 days of VSV-infection, no AAV-protected mice died until
at least 26 days after VSV infection. Similarly, whereas all 7 unpro-
tected mice died within 33 days (median survival 20 days), all but
Fig. 7. Effect of antiviral compounds and AAV-mIFN-β on infection of neuronal cultures. (A) Mouse brain neuron cultures were pretreated for 6 h with either chloroquine
(CLQ; 30 μM), MPA (300 μM), ribavirin (Rib; 300 μM), or IFN (100 IU/ml) and combinations thereof (CLQ-MPA-Rib). Cultures pretreated with AAV-mIFN-β were incubated for
10 days with a vector concentration of 5000 genomes per cell. Cultures were infected with an MOI of 1 of VSV-rp30 or VSV-CT9-M51, respectively. At 36 hpi, infected cells
were counted via ﬂuorescence microscopy. Bars indicate analysis of 10 microscopic ﬁelds, error bars expressed as SEM. (B) Neuronal marker NeuN was used to identify and
quantify infection rates in neurons. The percentage of mouse neurons (NeuNþ cells) in murine brain cultures infected with VSV was determined 20 hpi for unprotected cells,
and for cells protected by IFN-αA/D (100 IU/ml), ribavirin (Rib; 300 μM), AAV-mIFN-β (5000 genomes per cell), or AAV-mIFN-βþribavirin. Error bars, SEM. (C) Image panel of
representative micrographs showing corresponding phase contrast, NeuN immunostaining, and GFP images. Merged images show co-localization of VSV infection on
neurons (arrows) in control conditions (no pretreatment) and at much reduced rates in the treated cultures. nnn indicates po0.001signiﬁcance; n.s.¼not signiﬁcant (n¼10;
ANOVA with Bonferroni post-hoc analysis). Scale bar 50 μm.
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one of the 6 AAV-protected mice remained alive to the end of the
experiment 40 days after VSV infection; thus a marked and
statistically signiﬁcant (p¼0.002; Log-rank test) survival advan-
tage was conferred by AAV-mIFN-β. Body weight measurements
showed substantially less weight loss in AAV-protected mice as
well (po0.001; paired t-test), beginning 5 days after VSV infection
and continuing throughout the experiment as shown in Fig. 9B. At
the time of death (7–33 dpi for the VSV-only group) or at the end
of the experimental period at 40 dpi for AAV-mIFN-treated groups,
brains of mice were harvested and analyzed for tumor expansion
and signs of VSV infection. All 7 mice in the VSV-only group
showed large solid tumors (ranging 2–4 mm widest diameter)
with widespread VSV-CT9-M51 in the tumor (Fig. 9D). In contrast,
the group treated with AAV-mIFN-β before application of VSV-
CT9-M51 and sacriﬁced at the end of the experimental period
showed tumors in only two mice (2.2 and 2.5 mm diameter;
Fig. 9E); three mice had no trace of tumors (Fig. 9F). One mouse
died and its brain was not available for assessment. Assessing VSV
infection using GFP expression, we found consistent VSV infection
in all tumors in the control group, but found little to no VSV-
associated GFP in mice treated with AAV-mIFN at the end of the
observation period, suggesting AAV-mIFN can prevent
neurotoxicity-associated VSV spread without impairing the onco-
lytic activity of VSV on the tumor tissue.
Previous reports indicate little cross-reactivity between human
and mouse IFN (Berger Rentsch and Zimmer, 2011; Tedeschi et al.,
1986) suggesting the mouse IFN used here is selective for mice and
therefore may not exert a direct effect on the human tumor.
However, an antitumor effect of AAV-mIFN-β in this experiment
using human tumors could still be due to effects of IFN on the host
cells, for instance on tumor vascularization or on local immune
system activation. Therefore, the effect of AAV-mIFN-β on survival of
U87 tumor bearing mice was assessed. Compared to untreated mice
with U87 xenografts (n¼7), mice treated with AAV-mIFN-β alone
(n¼8) showed a signiﬁcant survival beneﬁt (median survival 27 days
vs 48 days, p¼0.0006, Wilcoxon test), indicating an antitumor effect
of AAV-mIFN-β on U87 xenografts (Fig. 10). Mice not protected by
AAV-mIFN-β, but treated with VSV-CT9-M51 (n¼5) had no signiﬁ-
cant survival beneﬁt over control animals. In contrast, in an addi-
tional group (n¼4) of U87 bearing mice treated systemically with
VSV-CT9-M51 after local CNS application of AAV-mIFN-β, median
survival was increased substantially from 48 days to 101 days by the
VSV-CT9-M51 application, a signiﬁcant survival beneﬁt over AAV-
mIFN-β alone (po0.05, Wilcoxon test) (Fig. 10). Together, these data
indicate that treatment of VSV-CT9-M51 combined with AAV-mIFN-β
provides a potential therapeutic effect on mouse survival when
bearing human glioblastoma xenografts.
Discussion
The brain can be particularly sensitive to both virus infection
and to antiviral drugs. In the present study we compared the
potential of a series of agents to limit VSV-associated neurotoxi-
city. We selected compounds reported to display antiviral activity
against rhabdoviruses (Bi and Reiss, 1995; Detje et al., 2009; Grant
and Sabina, 1972; Schlegel et al., 1982; Schnitzlein and Reichmann,
1980; Toltzis and Huang, 1986; Yamasaki et al., 2007) or against
other RNA viruses (Kolocouris et al., 1996; Ye et al., 2012). Of 12
drugs tested in vitro, IFN and ribavirin were the most effective at
blocking viral infection, replication, and at abrogating cell death.
Chloroquine, MPA, and Ara-A showed moderate efﬁcacy. Aspirin,
adenosine, amantadine, rimantadine, SNAP, and octylgallate showed
relatively little efﬁcacy. Whereas IFN and ribavirin were highly
effective in all tests, we found the ability of the moderately protective
drugs to inhibit VSV varied as a function of dose, timing of drug
Fig. 8. AAV-mIFN-β protects from VSV-CT9-M51 neurotoxicity in vivo. Direct
injection of antiviral drugs into the brain of mice (n¼5) resulted in no
observable toxicity or mortality (28 days observation) (A). Intracranial injection
of VSV-CT9-M51 resulted in mortality within 8 days; simultaneous intracranial
(i.c.) application of a mix of antiviral compounds that showed efﬁcacy in vitro
improved survival (B). Multiple intraperitoneal (i.p.) injections of the same
compound mix increased time to death but did not impact long-term survival (C,
dashed line). In contrast, intracranial injection of AAV-mIFN 10 days prior to
intracranial VSV-CT9-M51 challenge provided full protection from mortality (C,
full line). Body weight chart illustrates stable weight development in mice
protected with AAV-mIFN compared to control and i.p. drug receiving mice (only
survivor weights included) (D). Black triangles on X-axis indicate time points for
i.p. drug application. Error bars, SEM.
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administration, brain cell type, and/or VSV ﬁtness; these studies
serve to characterize these complex relationship between drug, virus,
and cell. The most effective compounds in vitro showed a protective
effect in vivo as well. Finally, we generated a potentially useful vector,
AAV expressing IFN, which was highly effective in protecting brain
from VSV-mediated toxicity in vitro and in vivo, and allowing a strong
survival advantage for tumor-bearing SCID mice treated with
oncolytic VSV.
Antiviral agents reduce VSV neurotoxicity
Ribavirin exerts its antiviral effects by multiple mechanisms,
including inhibition of viral RNA synthesis and mutagenesis of viral
RNA genomes; the different mechanisms may vary in their impor-
tance depending on the virus and the cell type (Hong and Cameron,
2002). Given that we see a near 100% suppression of the VSV GFP
reporter gene expression by low dose ribavirin even for non-
attenuated VSV-rp30 at 1 pfu/cell (Fig. 2A and B), as well as an
abrogation of viral replication (Fig. 5), we conclude that ribavirin has
Fig. 9. AAV-mIFN-β increases survival in VSV-CT9-M51 treated human glioblastoma-bearing SCID mice. Injection of AAV-mIFN-β or PBS (control) into the striatum was
accompanied by placement of human U87 glioblastoma xenografts at the same site. 14 days later, all mice received VSV-CT9-M51 via tail vein. Tumor targeting and
subsequent viral replication in the intracranial tumor xenograft result in progressive neurotoxicity and mortality in control mice (A, dashed line). In contrast, mice pretreated
with AAV-mIFN-β showed signiﬁcantly improved survival (A, solid line). There was a transient weight loss in AAV-mIFN-β pretreated mice compared to progressive weight
loss in the control group (B). Representative histological mouse brain sections are shown for tumor graft control (C), tumor graft treated with systemic VSV-CT9-M51 at 25
dpi (D); tumor graft treated with intracranial AAV-mIFN-β and systemic VSV-CT9-M51 at 39 dpi (E), and site of previous tumor graft placement after intracranial AAV-mIFN
and systemic VSV-CT9-M51 application 40 dpi (F).
Fig. 10. Long term control experiment assessing the effect of AAV-mIFN-β on
survival of U87 tumor bearing mice. SCID mice were stereotactically injected with
human U87 glioma cells into the right striatum. At the time of tumor placement,
two groups received AAV-mIFN-β injection into the same brain location. Two
groups received sham injection. 14 days later, VSV-CT9-M51 was injected via tail
vein into one group each, AAV-mIFN-β pretreated and mock treated. Compared to
untreated controls bearing tumors, AAV-mIFN-β treatment increased survival of
tumor bearing mice. Survival was signiﬁcantly improved by the additional treat-
ment with VSV-CT9-M51 in mice already injected with AAV-mIFN-β, compared to
tumor bearing mice treated only with AAV-mIFN-β.
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potent anti-VSV activity that operates early in the viral replication
cycle. Ribavirin efﬁcacy against VSV can vary depending on cell type
(Shah et al., 2010). Thus our ﬁnding of efﬁcacy in human brain cells is
signiﬁcant and supports ribavirin's possible utility in enhancing the
safety of therapeutic VSV applications in the brain. An additional
beneﬁt of ribavirin/IFN is that VSV did not develop mutants resistant
to co-treatment of IFN and ribavirin as long as therapeutic levels of
the drugs were maintained (Cuevas et al., 2005).
Besides IFN and ribavirin, several other compounds showed a
degree of efﬁcacy in different contexts. Pre-administration of Ara-
A and chloroquine to human brain cultures were nearly 100%
protective against VSV-rp30 at high dose, but showed little to no
effect at low dose. These results suggest that although these drugs
can have anti VSV activity, they both require a dose close to their
toxic concentration, thereby limiting their clinical efﬁcacy. MPA
showed only partial efﬁcacy in protecting human glial cultures
from tumor-adapted VSV-rp30, but was effective at low dose in
protecting from attenuated VSV-CT9-M51. MPA had only a tran-
sient effect on VSV replication, blocking progeny formation at 24
but not 48 hpi in human astrocytes.
Prolonged IFN activity via vector delivery signiﬁcantly reduces VSV
neurotoxicity
Type 1 IFNs upregulate a large cohort of cellular antiviral genes
and play a key role both peripherally and in the CNS in attenuating
VSV infection (Fensterl et al., 2012; Gresser et al., 1975). IFN may be
considered as one standard for VSV control. IFN action is generally
restricted to the species of origin (Maher et al., 2007). In order to test
the efﬁcacy of the same type 1 IFN on both human and mouse brain
cultures we used a recombinant IFN-αA/D that acts on both mouse
and human IFN receptors with comparable potency (Sigma I-4410
product sheet). The efﬁcacy of IFN for protection of brain against VSV
operated in a variety of contexts, thereby supporting its potential
utility for controlling VSV infection in the brain. Because peripherally
administered IFN may not readily cross the blood–brain barrier,
alternative methods of administration, for example intranasal, have
been explored (Ross et al., 2004).
Because IFN injections may have a short half-life, we generated a
recombinant AAV-based vector expressing mouse IFN-β; a single
application of this vector resulted in sustained protection of mouse
brain cultures from VSV infection for days and weeks. With some
reports indicating that IFN falls below detection threshold in serum
24 h after injection (Maher et al., 2007) the continuous delivery of
type 1 IFN via AAV vectors may itself serve as an antitumor gene
therapy agent (He et al., 2009; Meijer et al., 2009; Streck et al., 2006)
or as an antiviral agent in experimental models of hepatitis virus
infection (Berraondo et al., 2005). The potential for gene-delivered
IFN expression to control or prevent infection of the brain has not
been addressed before. The AAV-mIFN-β mediated protection from
direct intracranial VSV was substantially stronger and longer lasting
than direct IFN use. All mice receiving AAV-mIFN-β and intracranial
VSV survived, compared to only 20% in both i.c. and i.p. drug
application settings, respectively. The VSV-IFN-β currently in clinical
trial for liver cancer has been reported to display neurotoxicity in
cases in which it had gained access to the CNS via infection of
meningeal metastases in a rat model of multiple myeloma (Yarde
et al., 2013). In contrast, intracerebral application of AAV-mIFN-β
provided complete protection from VSV-CT9-M51. IFN may act at
some distance from its site of release within the CNS (van den Pol
et al., 2014), suggesting potential long distance actions within the
brain after local synthesis mediated by the AAV vector. Although
beyond the scope of our present study, this raises the question if
AAV-mIFN-β might also have potential for other rhabdovirus infec-
tions affecting the brain, for instance Chandipura or the VSV-related
rabies virus. Although a case of successful rabies treatment has been
reported (Willoughby Jr. et al., 2005), the majority of cases and
fulminant rabies are still considered untreatable (Jackson, 2009). In
such a scenario, the application of a safe vector expressing IFN in the
brain might hold some promise.
Alternatively, in the ﬁeld of oncology an IFN expressing vector
might offer the beneﬁt of strengthening the innate immunity of
the non-tumor tissue front around the tumor mass. Humans
undergoing cancer therapy often maintain an immune-
suppressed state and additional safety measures need to be
considered before oncolytic viruses can be applied, particularly
with CNS tumors. Such a scenario was mimicked in our in vivo
glioblastoma xenograft model employing immune compromised
SCID mice. We have previously shown successful targeting, infec-
tion, and destruction of intracranial human brain tumors
implanted in the brains of mice via systemically applied VSV-rp30 or
VSV-CT9-M51, respectively (Ozduman et al., 2009, 2008). But so far the
use of SCID mice has limited the use of these models for survival
studies, as the systemic immune system is required for VSV clearance
from brain (Bi et al., 1995; Ozduman et al., 2009). Our ﬁnding that
glioblastoma-bearing SCID mice treated with systemically applied
VSV-CT9-M51 survived longer when co-treated with AAV-mIFN-β
compared to control mice indicates that topically and continuously
released IFN has the potential to protect the brain even from awave of
new viral progeny being produced and released from infected and
lysed tumor cells. IFN might also act as an antitumor agent (Yoshida et
al., 2004). Human IFN-expressing AAV suppressed the growth of
human brain tumor cells (Meijer et al., 2009). Because IFN receptor
activation is selective for its species-speciﬁc IFN (Tedeschi et al., 1986;
Berger Rentsch and Zimmer, 2011), the mouse IFN in our study
would not be expected to exert a direct action on the human tumor
graft. However, our control experiments with AAV-mIFN-β treat-
ment of human glioblastoma xenograft mouse models revealed an
increase in survival compared to tumor bearing mice not treated
with AAV-IFN-β. This could be due to effects of mouse IFN on
vascularization, or some indirect effect on local innate immunity.
AAV expressing human IFN-β can signiﬁcantly inhibit human tumor
xenografts in the periphery (Streck et al., 2006) and in the brain of
immunocompromised mice (Maguire et al., 2008; Meijer et al.,
2009). In these studies with human IFN-β, the causes of tumor
inhibition were not delineated; however, an inhibition of angiogen-
esis was observed, and was postulated to result from either direct
inhibition of the tumor's ability to promote angiogenesis, or from a
hypothetical cross-species effect on the murine vasculature at high
concentrations of IFN. In the AAV vector used here, IFN was
constitutively expressed under control of a cytomegalovirus ie1
promoter. In a clinical context, as long term IFN exposure may exert
side effects within the brain, the use of an inducible promoter
driving AAV-IFN expression may merit consideration.
To our knowledge, a post infection effect of IFN on VSV infected
brain cultures had not been reported before. In vivo, application of
IFN to mice 4 days after intranasal inoculation with VSV resulted in
a survival beneﬁt (Gresser et al., 1975). Our data indicate that IFN
applied after initiation of VSV infection not only limits virus spread
to other cells but might have a protective effect even on cells
already infected. In light of the plethora of cellular responses
initiated by IFN signaling, including inhibition of VSV replication
cycle at early and late stages (Stark et al., 1998), a protective effect
of IFN after initiation of infection is conceivable. Ribavirin, which
has direct antiviral properties as a nucleoside analog disrupting
viral replication was also effective in protecting cultures up to 6 h
after VSV application, conﬁrming the view that ribavirin sup-
presses VSV progeny production (Toltzis and Huang, 1986).
In summary, we found that selected antiviral compounds can
protect glia and neuronal cultures from VSV mediated cell death.
IFN's protection of brain cells from VSV can be substantially
enhanced by prolonged IFN presence via an AAV vector-delivered
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transgene. A combination of viral vector expressed IFN together with
ribavirin gave the highest level of anti-virus protection to the brain.
Materials and methods
Cell culture
Primary cultures from adult human brain tissue were established
from temporal lobectomy specimens removed for epilepsy solely for
the beneﬁt of the patient as previously described (Wollmann et al.,
2007). The use was approved by the Yale University Human
Investigators Committee. Normal embryonic human astrocytes were
obtained from Sciencell (San Diego, CA). Cells were conﬁrmed as
astrocytes using GFAP immunostaining as previously described
(Ozduman et al., 2008). Murine brain cells were cultured from the
brains of E18-P0 Swiss Webster mice as described previously (Gao
and van den Pol, 2001). Glia cultures were maintained in minimal
essential medium (MEM) supplemented with 10% fetal bovine serum
and kept in a humidiﬁed atmosphere containing 5% CO2 at 37 1C.
Murine neuron-enriched cultures were maintained in neurobasal
medium supplemented with B27 (Gibco/Invitrogen); this medium
enhances neuronal survival and depresses glial cell division.
Drugs
Adenosine, amantadine, ara-A, aspirin, dansylcadaverine,
human IFN-αA/D, mycophenolic acid, ribavirin, rimantadine and
SNAP were obtained from Sigma-Aldrich (St. Louis, MO). Chlor-
oquine was obtained from MP Biomedicals (Solon, OH). All drugs
were diluted either in PBS, Ethanol or DMSO according to
manufacturers' speciﬁcations or, if unavailable, previously pub-
lished methods.
VSVs
Recombinant VSV strain VSV-CT9-M51 was generated by
Dr. J. Rose (Yale University, New Haven, CT) as previously described
(Wollmann et al., 2010), VSV-rp30 was derived from recombinant
VSV-G/GFP (Dalton and Rose, 2001) and generated by repetitive
adaptive passage on human U87 glioblastoma cells (Wollmann
et al., 2005).
rAAVs
The adeno-associated virus AAV-2 based vector expressing mouse
IFN was generated as follows: the pscAAV-CMV-tdTomato construct,
used to generate AAV-tdTomato virus, was assembled by blunting the
1.96 kb SnaBI-AﬂII fragment of pCMV-tdTomato (Clontech) and
cloning this into 4.2 kb SnaBI-digested and phosphatased fragment
of pscAAV-CMV-eGFP (a gift of Dr. R. Clark, Nationwide Children's
Hospital, Columbus, OH). The resulting construct contains the CMV
promoter in front of the tdTomato ORF, and this gene cassette lies
between the two AAV2-derived inverted terminal repeats (ITRs), one
of which is mutated to allow each virion to package a self-
complementary (palindromic) 5 kb single-stranded DNA genome,
allowing more efﬁcient transduction (Gray et al., 2011). The pscAAV-
CMV-mIFN-β construct used to generate AAV-mIFN-β virus was
generated by cloning the 780 bp SgrAI–MfeI fragment of pORF-
mIFN-β (InvivoGen. San Diego, CA) into the 4.8 kb AgeI–MfeI frag-
ment of pscAAV-CMV-eGFP. The resulting construct encodes a self-
complementary AAV in which the CMV ie1 promoter drives mIFN-β
expression. Plasmid constructs were sent to the Viral Vector Core
Laboratory at Nationwide Children's Hospital in Columbus, OH for
large-scale AAV vector recovery, puriﬁcation, quality control testing,
and accurate titration of DNAse-resistant particles (drp) per ml.
Constructs were packaged in the AAV2 capsid.
Analysis of viral infection and cytopathic effects
Cultures of normal human adult astroglia were plated over-
night in 24-well dishes at a density of 50,000 cells per well. Mouse
neuronal cultures were plated at a density of 5–10105 cells per
well in a 12-well dish and given 5–7 days for maturation. Medium
was replaced with drug containing solution and cultures were
incubated for 6 h. 5104 pfu VSV (5105 for neuronal cultures)
was added for a ﬁnal concentration of MOI 1. Viral infection was
analyzed based on ratio of cells expressing viral GFP reporter 48 h
post inoculation using an Olympus IX 71 ﬂuorescence microscope.
Cytopathic effects were monitored using phase contrast mode. A
microscope mounted Spot RT digital camera (Diagnostic Instru-
ments, Sterling Heights, MI) was used for image capturing. Photo-
micrographs were optimized for contrast and color using Adobe
Photoshop.
MTT-Assay
Cell viability was assessed using the Vybrant MTT-Assay kits
supplied by Invitrogen (Carlsbad, CA). Human astrocytes were
plated in 96-well dishes at a density of 10,000 cells per dish in
quadruplicates for each experimental condition. After incubation
overnight, medium was exchanged with phenol-red free MEM
containing the appropriate drug concentration. Virus was added
6 h later at an MOI of 0.1. MTT Compound A was added at 48 h,
followed by Compound B at 52 h post infection following manu-
facturer's instruction. Optical density measurements were per-
formed 12 h later at 570 nm using a Dynatech MR500 plate reader
(Dynatech Lab Inc, Alexandria, VA).
Propagation assay and plaque-assay
Human astrocytes were infected at an MOI 0.1 with VSV-rp30.
Supernatants were harvested at 24 and 48 h after infection and
frozen at 80 1C until further analysis. Serial dilutions of these
samples were plated on BHK-21 cells (ATCC, Manassas, VA)
followed by a 0.5% agar overlay and ﬂuorescent plaques were
assessed 24 h later.
AAV-mIFN-β VSV protection assay
25,000 murine glial cells per well were seeded in 24-well
plates. Medium was exchanged to medium containing either AAV-
tdTomato at 5000 genomes (measured as DNAse resistant particles
(drp))/cell, AAV-mIFN-β at 5000 or 500 genomes/cell, or IFN-αA/D
at 10 U/ml. Five days later, 50% of medium in all wells was
exchanged for fresh medium. After 4 additional days, plain growth
medium in one set of wells was exchanged for medium containing
IFN-αA/D at 10 U/ml. The next day, wells were infected with VSV-
G/GFP at MOI of 5. One day, two days, and three days post-
infection with VSV-G/GFP, triplicate wells were assessed for
infection and cytopathic effects using the microscope and camera
described above.
Immunocytochemistry for NeuN
20 h after VSV infection (MOI 1) of mouse neuronal cultures,
cells were ﬁxed with 4% paraformaldehyde. After permeabilization
with 0.4% Triton-X, cells were immunostained for murine neuron-
speciﬁc nuclear protein NeuN using primary antibody MAB377
(Chemicon, Temecula, CA) diluted 1:200, followed by secondary
staining with Alexa Fluor 568 anti-mouse IgG1 (Life Technologies,
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Grand Island, NY) diluted 1:200. Analysis of six microscopic ﬁelds
for each condition allowed identiﬁcation of red ﬂuorescent NeuN-
positive cells, each of which were then scored as GFP positive or
negative.
Animal procedures
Swiss-Webster mice were used for experiments involving immu-
nocompetent mice and CB17 SCID mice were used for xenograft brain
tumor models. All mice were obtained from Taconic Farms Inc.,
Germantown, NY. Intracranial injections and postoperative animal
care was conducted in accordance with the guidelines of the Yale
University Animal Care and Use Committee. Mice were anesthetized
using a combination of ketamine and xylazine (100 and 10mg/kg,
respectively) applied intraperitoneally. All intracranial injections were
performed on the left side, 1.5 mm lateral and 2.0 mm rostral of the
bregma at 2.0 mm depth using microsyringes from Hamilton (Reno,
NV) controlled by a stereotactic injector from Stoelting Co (Wood Dale,
IL). For testing efﬁcacy of intracranially applied antiviral drugs, 2.5 μl of
solution containing IFN-αA/D (1000 IU), ribavirin (7 mg/kg body
weight), and chloroquine (30 mM) were injected over a duration of
2.5 min and the needle was kept in place for an additional 15 min
before removal. Afterward, VSV-CT9-M51 was injected using the same
coordinates at a concentration of 1.5104 pfu per 250 nl inoculum.
For testing efﬁcacy of repetitive intraperitoneal applications of antiviral
compounds mice received an injection of 0.5 ml isotonic solution
containing IFN-αA/D (2500 IU), ribavirin (40 mg/kg) (Jeulin et al.,
2006), and chloroquine (50 mg/kg) every 48 h for a total of 4 injections
starting at the time of intracranial VSV-CT9-M51 application as
detailed above. For testing efﬁcacy of AAV-mIFN-β, 2 μl of a stock
solution containing 1013 genomes per ml were stereotactically injected
at the coordinates listed above. Control mice received injection of 2 μl
PBS. 14 days later, mice received stereotactic injection of 250 nl of VSV-
CT9-M51 containing 1.5104 pfu per inoculum at the same striatal
location. For treatment of an orthotopic brain tumor xenograft model
human glioblastoma cells stably expressing red ﬂuorescent reporter
gene dsRed rU87 were used (Ozduman et al., 2008). Tumors were
established by striatal injection of 1 μl of cell suspension containing
2104 cells. 15 min before tumor cell injection, mice received 2 μl of
either AAV-mIFN-β or PBS in the same location. 14 days later, all mice
received a single intravenous bolus of 100 μl containing 3107 pfu of
VSV-CT9-M51. Mice were monitored daily for body weight, food and
water consumption, motility, and presence of any neurological symp-
toms. Mice showing serious neurological dysfunction or dropping
below 75% of starting body weight were given an anesthetic overdose
and perfused transcardially with 4% paraformaldehyde.
Imaging
Serial sections of mouse brain were cut using a cryotome,
mounted with DAPI-containing embedding medium, and analyzed
for ﬂuorescence signals using the same microscope and camera
as above.
Statistics
Unless otherwise speciﬁed, data are expressed as mean and
standard error of the mean. Statistical analysis was performed
using t-test for pairwise comparison, or ANOVA for more than two
groups, respectively, using Kaleidagraph (Synergy software, Read-
ing, PA). Graph Pad Prism 6 (GraphPad software, San Diego, CA)
was used for Kaplan–Meier survival curves and for log-rank test to
analyze different groups for signiﬁcance.
Acknowledgments
We thank Yang Yang and Vitaliy Rogulin for technical facilitation
and John N. Davis for helpful suggestions on the manuscript. Support
is provided by the National Institutes of Health (CA124737,
CA161048, and CA175577), (A.V.); and K08CA169005 (J.P.).
References
Barber, G.N., 2004. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol.
17 (4), 516–527.
Bechmann, I., 2005. Failed central nervous system regeneration: a downside of
immune privilege? Neuromol. Med. 7 (3), 217–228.
Berger Rentsch, M., Zimmer, G., 2011. A vesicular stomatitis virus replicon-based
bioassay for the rapid and sensitive determination of multi-species type I
interferon. PLoS One 6, e25858.
Berraondo, P., Ochoa, L., Crettaz, J., Rotellar, F., Vales, A., Martinez-Anso, E.,
Zaratiegui, M., Ruiz, J., Gonzalez-Aseguinolaza, G., Prieto, J., 2005. IFN-alpha
gene therapy for woodchuck hepatitis with adeno-associated virus: differences
in duration of gene expression and antiviral activity using intraportal or
intramuscular routes. Mol. Ther. 12 (1), 68–76.
Bi, Z., Barna, M., Komatsu, T., Reiss, C.S., 1995. Vesicular stomatitis virus infection of
the central nervous system activates both innate and acquired immunity.
J. Virol. 69 (10), 6466–6472.
Bi, Z., Reiss, C.S., 1995. Inhibition of vesicular stomatitis virus infection by nitric
oxide. J. Virol. 69 (4), 2208–2213.
Chen, N., Warner, J.L., Reiss, C.S., 2000. NSAID treatment suppresses VSV propaga-
tion in mouse CNS. Virology 276 (1), 44–51.
Clarke, D.K., Nasar, F., Lee, M., Johnson, J.E., Wright, K., Calderon, P., Guo, M., Natuk,
R., Cooper, D., Hendry, R.M., Udem, S.A., 2007. Synergistic attenuation of
vesicular stomatitis virus by combination of speciﬁc G gene truncations and
N gene translocations. J. Virol. 81 (4), 2056–2064.
Coombs, K., Mann, E., Edwards, J., Brown, D.T., 1981. Effects of chloroquine and
cytochalasin B on the infection of cells by Sindbis virus and vesicular stomatitis
virus. J. Virol. 37, 1060–1065.
Cuevas, J.M., Sanjuan, R., Moya, A., Elena, S.F., 2005. Mode of selection and
experimental evolution of antiviral drugs resistance in vesicular stomatitis
virus. Infect. Genet. Evol. 5 (1), 55–65.
Dalton, K.P., Rose, J.K., 2001. Vesicular stomatitis virus glycoprotein containing the
entire green ﬂuorescent protein on its cytoplasmic domain is incorporated
efﬁciently into virus particles. Virology 279 (2), 414–421.
Delhaye, S., Paul, S., Blakqori, G., Minet, M., Weber, F., Staeheli, P., Michiels, T., 2006.
Neurons produce type I interferon during viral encephalitis. Proc. Natl. Acad.
Sci. USA 103 (20), 7835–7840.
Detje, C.N., Meyer, T., Schmidt, H., Kreuz, D., Rose, J.K., Bechmann, I., Prinz, M.,
Kalinke, U., 2009. Local type I IFN receptor signaling protects against virus
spread within the central nervous system. J. Immunol. 182 (4), 2297–2304.
Dille, B.J., Johnson, T.C., 1982. Inhibition of vesicular stomatitis virus glycoprotein
expression by chloroquine. J. Gen. Virol. 62 (Pt 1), 91–103.
Fensterl, V., Wetzel, J.L., Ramachandran, S., Ogino, T., Stohlman, S.A., Bergmann, C.C.,
Diamond, M.S., Virgin, H.W., Sen, G.C., 2012. Interferon-induced Iﬁt2/ISG54
protects mice from lethal VSV neuropathogenesis. PLoS Pathog. 8 (5), e1002712.
Flanagan, E.B., Zamparo, J.M., Ball, L.A., Rodriguez, L.L., Wertz, G.W., 2001. Rearran-
gement of the genes of vesicular stomatitis virus eliminates clinical disease in
the natural host: new strategy for vaccine development. J. Virol. 75 (13),
6107–6114.
Gao, X.B., van den Pol, A.N., 2001. Melanin concentrating hormone depresses
synaptic activity of glutamate and GABA neurons from rat lateral hypothala-
mus. J. Physiol. 533 (Pt 1), 237–252.
Geisbert, T.W., Feldmann, H., 2011. Recombinant vesicular stomatitis virus-based
vaccines against Ebola and Marburg virus infections. J. Infect. Dis. 204 (Suppl.
3), S1075–S1081.
Grant, J.A., Sabina, L.R., 1972. Inhibition of vesicular stomatitis virus replication by
9-beta-D-arabinofuranosyladenine. Antimicrob. Agents Chemother. 2 (3),
201–205.
Gray, S.J., Foti, S.B., Schwartz, J.W., Bachaboina, L., Taylor-Blake, B., Coleman, J.,
Ehlers, M.D., Zylka, M.J., McCown, T.J., Samulski, R.J., 2011. Optimizing promo-
ters for recombinant adeno-associated virus-mediated gene expression in the
peripheral and central nervous system using self-complementary vectors. Hum.
Gene Ther. 22 (9), 1143–1153.
Gresser, I., Tovey, M.G., Bourali-Maury, C., 1975. Efﬁcacy of exogenous interferon
treatment initiated after onset of multiplication of vesicular stomatitis virus in
the brains of mice. J. Gen. Virol. 27 (3), 395–398.
Harada, H., Willison, K., Sakakibara, J., Miyamoto, M., Fujita, T., Taniguchi, T., 1990.
Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1)
and repressor (IRF-2) genes are developmentally regulated. Cell 63 (2),
303–312.
Hastie, E., Grdzelishvili, V.Z., 2012. Vesicular stomatitis virus as a ﬂexible platform
for oncolytic virotherapy against cancer. J. Gen. Virol. 93 (Pt 12), 2529–2545.
He, L.F., Wang, Y.G., Xiao, T., Zhang, K.J., Li, G.C., Gu, J.F., Chu, L., Tang, W.H., Tan, W.S.,
Liu, X.Y., 2009. Suppression of cancer growth in mice by adeno-associated virus
vector-mediated IFN-beta expression driven by hTERT promoter. Cancer Lett.
286 (2), 196–205.
G. Wollmann et al. / Virology 475 (2015) 1–14 13
Hong, Z., Cameron, C.E., 2002. Pleiotropic mechanisms of ribavirin antiviral
activities. Prog. Drug Res. 59, 41–69.
Jackson, A.C., 2009. Therapy of rabies encephalitis. Biomedica 29 (2), 169–176.
Jeulin, H., Grancher, N., Kedzierewicz, F., Le Faou, A.E., Venard, V., 2006. Evaluation
by Q-RTPCR of the efﬁcacy of ribavirin complexed with beta-cyclodextrin
against measles virus in a mouse encephalitis model. Pathol. Biol. (Paris)
54 (10), 541–544.
Johnson, J.E., Nasar, F., Coleman, J.W., Price, R.E., Javadian, A., Draper, K., Lee, M.,
Reilly, P.A., Clarke, D.K., Hendry, R.M., Udem, S.A., 2007. Neurovirulence
properties of recombinant vesicular stomatitis virus vectors in non-human
primates. Virology 360 (1), 36–49.
Kallfass, C., Ackerman, A., Lienenklaus, S., Weiss, S., Heimrich, B., Staeheli, P., 2012.
Visualizing production of beta interferon by astrocytes and microglia in brain of
La Crosse virus-infected mice. J. Virol. 86 (20), 11223–11230.
Kolocouris, N., Kolocouris, A., Foscolos, G.B., Fytas, G., Neyts, J., Padalko, E., Balzarini,
J., Snoeck, R., Andrei, G., De Clercq, E., 1996. Synthesis and antiviral activity
evaluation of some new aminoadamantane derivatives. 2. J. Med. Chem. 39 (17),
3307–3318.
Lichty, B.D., Power, A.T., Stojdl, D.F., Bell, J.C., 2004. Vesicular stomatitis virus: re-
inventing the bullet. Trends Mol. Med. 10 (5), 210–216.
Lyles, D.S., Rupprecht, C.E., 2007. Rhabdoviridae. In: Knipe, D.M., Howley, P.M.
(Eds.), Fields Virology, 5th ed. Lippincott, Williams and Wilkins, Philadelphia.
Maguire, C.A., Meijer, D.H., LeRoy, S.G., Tierney, L.A., Broekman, M.L.D., Costa, F.F.,
Breakeﬁeld, X.O., Stemmer-Rachamimov, A., Sena-Esteves, M., 2008. Preventing
growth of brain tumors by creating a zone of resistance. Mol. Ther. 16,
1695–1702.
Maher, S.G., Romero-Weaver, A.L., Scarzello, A.J., Gamero, A.M., 2007. Interferon:
cellular executioner or white knight? Curr. Med. Chem. 14 (12), 1279–1289.
Mato, J.M., Pencev, D., Vasanthakumar, G., Schiffmann, E., Pastan, I., 1983. Inhibitors
of endocytosis perturb phospholipid metabolism in rabbit neutrophils and
other cells. Proc. Natl. Acad. Sci. USA 80, 1929–1932.
McKenna, P.M., McGettigan, J.P., Pomerantz, R.J., Dietzschold, B., Schnell, M.J., 2003.
Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases.
Curr. HIV Res. 1 (2), 229–237.
Meijer, D.H., Maguire, C.A., LeRoy, S.G., Sena-Esteves, M., 2009. Controlling brain
tumor growth by intraventricular administration of an AAV vector encoding
IFN-beta. Cancer Gene Ther. 16 (8), 664–671.
Muik, A., Kneiske, I., Werbizki, M., Wilﬂingseder, D., Giroglou, T., Ebert, O., Kraft, A.,
Dietrich, U., Zimmer, G., Momma, S., von Laer, D., 2011. Pseudotyping vesicular
stomatitis virus with lymphocytic choriomeningitis virus glycoproteins
enhances infectivity for glioma cells and minimizes neurotropism. J. Virol. 85
(11), 5679–5684.
Muik, A., Dold, C., Geiß, Y., Volk, A., Werbizki, M., Dietrich, U., von Laer, D., 2012.
Semireplication-competent vesicular stomatitis virus as a novel platform for
oncolytic virotherapy. J. Mol. Med. 90 (8), 959–970.
Ozduman, K., Wollmann, G., Ahmadi, S.A., van den Pol, A.N., 2009. Peripheral
immunization blocks lethal actions of vesicular stomatitis virus within the
brain. J. Virol. 83 (22), 11540–11549.
Ozduman, K., Wollmann, G., Piepmeier, J.M., van den Pol, A.N., 2008. Systemic
vesicular stomatitis virus selectively destroys multifocal glioma and metastatic
carcinoma in brain. J. Neurosci. 28 (8), 1882–1893.
Paul, S., Ricour, C., Sommereyns, C., Sorgeloos, F., Michiels, T., 2007. Type I
interferon response in the central nervous system. Biochimie 89 (6–7),
770–778.
Pérez, L., Carrasco, L., 1994. Involvement of the vacuolar H(þ)-ATPase in animal
virus entry. J. Gen. Virol. 75 (Pt 10), 2595–2606.
Pestka, S., 1986. Interferon standards and general abbreviations. Methods Enzymol.
119, 14–23.
Publicover, J., Ramsburg, E., Rose, J.K., 2004. Characterization of nonpathogenic, live,
viral vaccine vectors inducing potent cellular immune responses. J. Virol. 78
(17), 9317–9324.
Publicover, J., Ramsburg, E., Rose, J.K., 2005. A single-cycle vaccine vector based on
vesicular stomatitis virus can induce immune responses comparable to those
generated by a replication-competent vector. J. Virol. 79 (21), 13231–13238.
Roberts, A., Buonocore, L., Price, R., Forman, J., Rose, J.K., 1999. Attenuated vesicular
stomatitis viruses as vaccine vectors. J. Virol. 73 (5), 3723–3732.
Rose, N.F., Marx, P.A., Luckay, A., Nixon, D.F., Moretto, W.J., Donahoe, S.M.,
Monteﬁori, D., Roberts, A., Buonocore, L., Rose, J.K., 2001. An effective AIDS
vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell
106 (5), 539–549.
Ross, T.M., Martinez, P.M., Renner, J.C., Thorne, R.G., Hanson, L.R., Frey 2nd, W.H.,
2004. Intranasal administration of interferon beta bypasses the blood–brain
barrier to target the central nervous system and cervical lymph nodes: a non-
invasive treatment strategy for multiple sclerosis. J. Neuroimmunol. 151 (1–2),
66–77.
Schlegel, R., Dickson, R.B., Willingham, M.C., Pastan, I.H., 1982. Amantadine and
dansylcadaverine inhibit vesicular stomatitis virus uptake and receptor-
mediated endocytosis of alpha 2-macroglobulin. Proc. Natl. Acad. Sci. USA
79 (7), 2291–2295.
Schnitzlein, W.M., Reichmann, M.E., 1980. Inhibition of vesicular stomatitis virus
replication by adenosine. Virology 103 (1), 123–137.
Shah, N.R., Sunderland, A., Grdzelishvili, V.Z., 2010. Cell type mediated resistance of
vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One 5 (6), e11265.
Stark, G.R., Kerr, I.M., Williams, B.R., Silverman, R.H., Schreiber, R.D., 1998. How cells
respond to interferons. Annu. Rev. Biochem. 67, 227–264.
Stojdl, D.F., Lichty, B.D., tenOever, B.R., Paterson, J.M., Power, A.T., Knowles, S.,
Marius, R., Reynard, J., Poliquin, L., Atkins, H., Brown, E.G., Durbin, R.K.,
Durbin, J.E., Hiscott, J., Bell, J.C., 2003. VSV strains with defects in their ability
to shutdown innate immunity are potent systemic anti-cancer agents. Cancer
Cell 4 (4), 263–275.
Stollar, V., Malinoski, F., 1981. The effects of adenosine and guanosine on the
replication of Sindbis and vesicular stomatitis viruses in Aedes albopictus cells.
Virology 115, 57–66.
Streck, C.J., Dickson, P.V., Ng, C.Y., Zhou, J., Hall, M.M., Gray, J.T., Nathwani, A.C.,
Davidoff, A.M., 2006. Antitumor efﬁcacy of AAV-mediated systemic delivery of
interferon-beta. Cancer Gene Ther. 13 (1), 99–106.
Superti, F., Seganti, L., Pana, A., Orsi, N., 1985. Effect of amantadine on rhabdovirus
infection. Drugs Exp. Clin. Res. 11 (1), 69–74.
Tedeschi, B., Barrett, J.N., Keane, R.W., 1986. Astrocytes produce interferon that
enhances the expression of H-2 antigens on a subpopulation of brain cells.
J. Cell Biol. 102 (6), 2244–2253.
Toltzis, P., Huang, A.S., 1986. Effect of ribavirin on macromolecular synthesis in
vesicular stomatitis virus-infected cells. Antimicrob. Agents Chemother. 29 (6),
1010–1016.
Uozaki, M., Yamasaki, H., Katsuyama, Y., Higuchi, M., Higuti, T., Koyama, A.H., 2007.
Antiviral effect of octyl gallate against DNA and RNA viruses. Antiviral Res. 73,
85–91. http://dx.doi.org/10.1016/j.antiviral.2006.07.010.
van den Pol, A.N., Dalton, K.P., Rose, J.K., 2002. Relative neurotropism of a
recombinant rhabdovirus expressing a green ﬂuorescent envelope glycopro-
tein. J. Virol. 76 (3), 1309–1327.
van den Pol, A.N., Davis, J.N., 2013. Highly attenuated recombinant vesicular
stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity.
J. Virol. 87, 1019–1034.
van den Pol, A.N., Ozduman, K., Wollmann, G., Ho, W.S., Simon, I., Yao, Y., Rose, J.K.,
Ghosh, P., 2009. Viral strategies for studying the brain, including a replication-
restricted self-amplifying delta-G vesicular stomatis virus that rapidly
expresses transgenes in brain and can generate a multicolor golgi-like expres-
sion. J. Comp. Neurol. 516 (6), 456–481.
van den Pol, A.N., Ding, S., Robek, M.D., 2014. Long distance interferon signaling
within the brain blocks virus spread. J. Virol. 88, 3695–3704.
Wang, J., Campbell, I.L., 2005. Innate STAT1-dependent genomic response of
neurons to the antiviral cytokine alpha interferon. J. Virol. 79 (13), 8295–8302.
Willoughby Jr., R.E., Tieves, K.S., Hoffman, G.M., Ghanayem, N.S., Amlie-Lefond, C.M.,
Schwabe, M.J., Chusid, M.J., Rupprecht, C.E., 2005. Survival after treatment of
rabies with induction of coma. N. Engl. J. Med. 352 (24), 2508–2514.
Wollmann, G., Davis, J.N., Bosenberg, M.W., van den Pol, A.N., 2013. Vesicular
stomatitis virus variants selectively infect and kill human melanomas but not
normal melanocytes. J. Virol. 87, 6644–6659.
Wollmann, G., Robek, M.D., van den Pol, A.N., 2007. Variable deﬁciencies in the
interferon response enhance susceptibility to vesicular stomatitis virus onco-
lytic actions in glioblastoma cells but not in normal human glial cells. J. Virol.
81 (3), 1479–1491.
Wollmann, G., Rogulin, V., Simon, I., Rose, J.K., van den Pol, A.N., 2010. Some
attenuated variants of vesicular stomatitis virus show enhanced oncolytic
activity against human glioblastoma cells relative to normal brain cells. J. Virol.
84 (3), 1563–1573.
Wollmann, G., Tattersall, P., van den Pol, A.N., 2005. Targeting human glioblastoma
cells: comparison of nine viruses with oncolytic potential. J. Virol. 79 (10),
6005–6022.
Yamasaki, H., Uozaki, M., Katsuyama, Y., Utsunomiya, H., Arakawa, T., Higuchi, M.,
Higuti, T., Koyama, A.H., 2007. Antiviral effect of octyl gallate against inﬂuenza
and other RNA viruses. Int. J. Mol. Med. 19 (4), 685–688.
Yarde, D.N., Naik, S., Nace, R.A., Peng, K.W., Federspiel, M.J., Russell, S.J., 2013.
Meningeal myeloma deposits adversely impact the therapeutic index of an
oncolytic VSV. Cancer Gene Ther. 20 (11), 616–621.
Ye, L., Li, J., Zhang, T., Wang, X., Wang, Y., Zhou, Y., Liu, J., Parekh, H.K., Ho, W., 2012.
Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic
cells. Virus Res. 168 (1–2), 33–40.
Yin, J., Gardner, C.L., Burke, C.W., Ryman, K.D., Klimstra, W.B., 2009. Similarities and
differences in antagonism of neuron alpha/beta interferon responses by
Venezuelan equine encephalitis and Sindbis alphaviruses. J. Virol. 83 (19),
10036–10047.
Yoshida, J., Mizuno, M., Wakabayashi, T., 2004. Interferon-beta gene therapy for
cancer: basic research to clinical application. Cancer Sci. 95 (11), 858–865.
G. Wollmann et al. / Virology 475 (2015) 1–1414
